|
Synonyms: CGP 20712A | CGP-20712A
Compound class:
Synthetic organic
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor. Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733] |
|
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385] |
|
3. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 144 (3): 317-22. [PMID:15655528] |
|
4. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. PLoS ONE, 5 (11): e15487. [PMID:21152092] |
|
5. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker. Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077] |
|
6. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020)
Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers. ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874] |
|
7. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J, 31 (7): 3150-3166. [PMID:28400472] |
|
8. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341] |
|
9. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011)
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J, 25 (12): 4486-97. [PMID:21865315] |
|
10. Baker JG, Lim VJY, Proudman RGW, Giese FNZ, Kolb P. (2025)
Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor. Mol Pharmacol, 107 (11): 100081. [PMID:41289653] |
|
11. Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ. (2008)
Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor. Mol Pharmacol, 74 (5): 1246-60. [PMID:18687809] |
|
12. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PLoS One, 8 (11): e77582. [PMID:24250787] |
|
13. Baker JG, Proudman RG, Hill SJ. (2014)
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Mol Pharmacol, 85 (5): 811-29. [PMID:24608857] |
|
14. Buxton BF, Jones CR, Molenaar P, Summers RJ. (1987)
Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol, 92 (2): 299-310. [PMID:2823947] |
|
15. Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE. (1999)
Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther, 290 (2): 649-55. [PMID:10411574] |
|
16. Louis SN, Nero TL, Iakovidis D, Jackman GP, Louis WJ. (1999)
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol, 367 (2-3): 431-5. [PMID:10079020] |
|
17. Mistry SN, Baker JG, Fischer PM, Hill SJ, Gardiner SM, Kellam B. (2013)
Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists. J Med Chem, 56 (10): 3852-65. [PMID:23614528] |
|
18. Proudman RGW, Baker JG. (2025)
A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD. Pharmacol Res Perspect, 13 (5): e70154. [PMID:40887869] |
|
19. Sato T, Baker J, Warne T, Brown GA, Leslie AG, Congreve M, Tate CG. (2015)
Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound β1-Adrenergic Receptor. Mol Pharmacol, 88 (6): 1024-34. [PMID:26385885] |
|
20. Soave M, Cseke G, Hutchings CJ, Brown AJH, Woolard J, Hill SJ. (2018)
A monoclonal antibody raised against a thermo-stabilised β1-adrenoceptor interacts with extracellular loop 2 and acts as a negative allosteric modulator of a sub-set of β1-adrenoceptors expressed in stable cell lines. Biochem Pharmacol, 147: 38-54. [PMID:29102678] |
|
21. Tricomi J, Landini L, Nieddu V, Cavallaro U, Baker JG, Papakyriakou A, Richichi B. (2023)
Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships. Eur J Med Chem, 246: 114961. [PMID:36495629] |